QLQX capsule has been used in the clinical treatment of arrhythmia (Wei et al., 2012), and experiments in a rabbit model of electrical stimulation-induced AF showed that QLQX effectively rescued the pacing-mediated downregulation of the L-type dihydropyridine receptor (DHPR) and reduced AF inducibility (Tingting et al., 2019). This evidence concerns the gene QDPR and atrial fibrillation.